Ablynx establishes US subsidiary
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Ablynx NV established Ablynx Inc., a subsidiary in the U.S.
Daniel Schneider will head the unit as general manager with the goal of commercializing caplacizumab in North America.
If approved by regulatory authorities, caplacizumab would be the first therapeutic specifically indicated to treat acquired thrombotic thrombocytopenic purpura.
